ArticleCNS neuroscience & therapeutics2025
Lymphoplasmapheresis for Steroid-Refractory Neuromyelitis Optica Spectrum Disorder: A Real-World Multicenter Study in China.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The Impact of Bariatric Surgery on Obesity-Associated NETosis, Immune Modulation, and Cardiovascular Risk Reduction.Obesity surgery · 2026Review
- The Statin Paradox: Drivers and Consequences of Therapy Discontinuation.Metabolites · 2026Review
- Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody-Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation.CNS neuroscience & therapeutics · 2026Article
- Targeting JAK/STAT signalling with cold atmospheric plasma: a potential therapy for systemic lupus erythematosus.Expert reviews in molecular medicine · 2026Review
- Inflammatory Mammary Carcinoma in a Captive Bengal Tiger (Animals : an open access journal from MDPI · 2026Article
- Subsequent treatment strategies following rituximab-resistance in AQP4-IgG+ neuromyelitis optica spectrum disorder: a case series.Frontiers in immunology · 2026Article
- Detection of RBC-bound antibodies using flow cytometry and their correlation with HLA polymorphism.Frontiers in immunology · 2026Article
- Reversal of refractory systemic lupus erythematosus-associated immune thrombotic thrombocytopenic purpura and cerebritis via optimized lymphoplasmapheresis: a case report and literature review.Frontiers in immunology · 2026Review
- First application of whole blood exchange-lymphoplasmapheresis combined transfusion for restoring immune homeostasis of ceftriaxone-induced hemolytic crisis: a case report.Frontiers in immunology · 2026Article
- The therapeutic potential of atorvastatin in treatment ofFrontiers in veterinary science · 2026Article
- Lymphoplasmapheresis for Steroid-Refractory Neuromyelitis Optica Spectrum Disorder: A Real-World Multicenter Study in China.CNS neuroscience & therapeutics · 2025Article
- Neuroimmunological overlap syndromes in optic neuritis, myelitis, and connective tissue diseases.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundLymphoplasmapheresis (LPE), an innovative hemopurification technique that integrates conventional plasma exchange (PE) with lymphopheresis, has demonstrated efficacy in various neuroimmune disorders by removing excessive or dysfunctional lymphocytes and pathological components from plasma. This study aimed to unveil the mechanisms of LPE and provide additional clinical evidence supporting its use in the acute treatment of steroid-refractory NMOSD.
methodsThis study included 105 acute-stage steroid-refractory NMOSD patients. The efficacy and potential mechanisms of LPE were clarified by monitoring severity scores, clinical laboratory parameters, immune cell subsets, and cytokine levels.
resultsIn the retrospective cohort, LPE proved effective in treating acute steroid-refractory NMOSD and was non-inferior to PE. In the prospective cohort, LPE significantly decreased Expanded Disability Status Scale (EDSS) and Activities of Daily Living (ADL) scores (p < 0.05). In both cohorts, erythrocytes, hemoglobin, and platelets decreased. Notably, LPE significantly reduced the proportions of activated platelet-adherent monocytes, plasmablasts, and memory B cells, while increasing that of naive CD8
conclusionWhile further validation is warranted, our findings suggest that LPE could represent a potential acute-phase treatment strategy for patients with AQP4-Ab
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.